Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 0 (0%) Market Cap: 275.10 Mil Enterprise Value: 126.27 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 50/100

Q3 2023 Lexicon Pharmaceuticals Inc Earnings Call Transcript

Nov 08, 2023 / 01:00PM GMT
Release Date Price: €4.1
Operator

Good day, and welcome to the Lexicon Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. (Operator Instructions) Please note that today's event is being recorded.

I would now like to turn the conference over to Carrie Siragusa. Please go ahead.

Carrie Siragusa
Lexicon Pharmaceuticals, Inc. - Former Executive Director of Corporate Strategy & IR

Thank you, Craig. Good morning, and welcome to the Lexicon Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. Joining me today are Lonnel Coats, Lexicon's Chief Executive Officer; Jeff Wade, Lexicon's President and Chief Financial Officer; Dr. Craig Granowitz, Lexicon's Senior Vice President and Chief Medical Officer; and Tom Garner, Lexicon's Senior Vice President and Chief Commercial Officer.

Earlier this morning, Lexicon issued a press release announcing our financial results for the third quarter of 2023, which is available on our website at www.lexpharma.com and through our SEC filings. A

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot